Antibodies, viruses and vaccines

Nature Reviews Immunology

Volumn 2, Issue 9, 2002, Pages 706-713

  Burton, Dennis R ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; SUBUNIT VACCINE; VIRUS VACCINE; ANTIVIRUS AGENT; VIRUS ANTIBODY;

AGAMMAGLOBULINEMIA; ANTIBODY RESPONSE; ANTIVIRAL ACTIVITY; CELLULAR IMMUNITY; DNA LIBRARY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; IN VIVO STUDY; MEMORY CELL; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VACCINATION; VIRUS INFECTION; VIRUS NEUTRALIZATION; ANIMAL; BIOSYNTHESIS; DRUG DESIGN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY;

ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; DRUG DESIGN; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; VACCINATION; VIRAL VACCINES; VIRUS DISEASES;

EID: 0036719574     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri891     Document Type: Review

References (85)

1. Oldstone, M. B. A. Viruses, Plagues and History (Oxford University Press, New York, 1998).
2. Whitton, J. L. & Oldstone, M. B. A. in Fields Virology (eds Knipe, D. M. & Howley, P. M.) 285-320 (Lippincott Williams, Philadelphia, 2001).
3. Zinkernagel, R. M. Maternal antibodies, childhood infections and autoimmune diseases. N. Engl. J. Med. 345, 1331-1335 (2001).
4. Zinkernagel, R. M. et al. Neutralizing antiviral antibody responses. Adv. Immunol. 79, 1-53 (2001).
5. Koff, W. C. & Fauci, A. S. Human trials of AIDS vaccines: current status and future directions. AIDS 3, S125-S129 (1989).
6. Cohen, J. AIDS research Merck reemerges with a bold AIDS vaccine effort. Science 292, 24-25 (2001).
7. + T-cell approach feasible? Nature Rev. Immunol. 2, 283-291 (2002).
8. Robinson, H. L. New hope for an AIDS vaccine. Nature Rev. Immunol., 2, 239-250 (2002).
9. Letvin, N. L., Barouch, D. H. & Montefiori, D. C. Prospects for vaccine protection against HIV-1 infection and AIDS. Annu. Rev. Immunol. 20, 73-99 (2002).
10. Dimmock, N. J. Update on the neutralization of animal viruses. Rev. Med. Virol. 5, 165-179 (1995).
11. Parren, P. W. H. I. and Burton, D. R. The anti-viral activity of antibodies in vitro and in vivo. Adv. Immunol. 77, 195-262 (2001).
12. Burnet, F. M., Keogh, E. V. & Lush, D. The immunological reactions of the filterable viruses. Austral. J. Exp. Biol. Med. Sci. 15, 231-368 (1937).
13. Spear, G. T., Hart, M., Olinger, G. G., Hashemi, F. B. & Saifuddin, M. The role of the complement system in virus infections. Curr. Top. Microbiol. Immunol. 260, 229-245 (2001).
14. McCullough, K. C., Parkinson, D. & Crowther, J. R. Opsonization-enhanced phagocytosis of foot-and-mouth disease virus. Immunology 65, 187-191 (1988).
15. Fujinami, R. S. & Oldstone, M. B. Antiviral antibody reacting on the plasma membrane alters measles virus expression inside the cell. Nature 279, 529-530 (1979).
16. Levine, B. et al. Antibody-mediated clearance of alphavirus infection from neurons. Science 254, 856-860 (1991).
17. Gerhard, W. The role of the antibody response in influenza virus infection. Curr. Top. Microbiol. Immunol. 260, 171-190 (2001).
18. Pantaleo, G. et al. Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission. Eur. J. Immunol. 25, 226-231 (1995).
19. Burioni, R. Williamson, R. A., Sanna, P. P., Bloom, F. E. & Burton, D. R. Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro. Proc. Natl. Acad. Sci. USA 91, 355-359 (1994).
20. Hooks, J. J., Burris, W. Hayashi, K., Geis, S. & Notkins, A. L. Viral spread in the presence of neutralization antibody: mechanisms of persistence in foamy virus infection. Infect. Immun. 14, 1172-1178 (1976).
21. Hezareh, M., Hessell, A. J., Jensen, R., van de Winkel, J. G. J. & Parren, P. W. H. I. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 75, 12161-12168 (2001).
22. Henchal, E. A., Henchal, L. S. & Schresinger, J. J. Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J. Gen. Virol. 69, 2101-2107 (1988).
23. Manzanec, M. B., Lamm, M. E., Lyn, D., Porter, A. & Bedrud, J. G. Comparison of IgA versus IgG monoclonal antibodies for passive immunization of the murine respiratory tract. Virus. Res. 23, 1-12 (1992).
24. Fujioka, H. et al. Immunocytochemical colocalization of specific immunoglobulin A with sendai virus protein in infected polarized epithelium. J. Exp. Med. 188, 1223-1229 (1998).
25. Manzanec, M. B., Coudret, C. L. & Fletcher, D. R. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J. Virol. 69, 1339-1343 (1995).
26. Kato, H., Kato, R. Fujihashi, K. & McGhee, J. R. Role of mucosal antibodies in viral infections. Curr. Top. Microbiol. Immunol. 260, 201-228 (2001).
27. Bomsel, M. et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dlgA or IgM. Immunity 9, 277-287 (1998).
28. Hawkes, R. A. & Lafferty, K. J. The enhancement of virus infectivity by antibody. Virology 33, 250-261 (1967).
29. Halstead, S. B. Immune enhancement of viral infection. Prog. Allergy 31, 301-364 (1982).
30. Morens, D. M., Halstead, S. B. & Marchette, N. J. Profiles of antibody-dependent enhancement of dengue virus type 2 infection. Microb. Pathog. 3, 231-237 (1987).
31. Sullivan, N., Sun, Y., Li, J., Hofmann, W. & Sodroski, J. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell-line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 69, 4413-4422 (1995).
32. Sullivan, N. J. Antibody-mediated enhancement of viral disease. Curr. Top. Microbiol Immunol. 260, 145-169 (2001).
33. Kliks, S. C., Nimmanitya, S., Nisalak, A. & Burke, D. S. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop Med. Hyg. 38, 411-419 (1988).
34. Prince, G. A., Horswood, P. L. & Chanock, R. M. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J. Virol. 55, 517-520 (1985).
35. Parren, P. W. H. I. et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75, 8340-8347 (2001).
36. Nishimura, Y. et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J. Virol. 76, 2123-2130 (2002).
37. Wright, K. E. & Buchmeier, M. J. Antiviral antibodies attenuate T-cell-mediated immunopathology following acute lymphocytic choriomeningitis virus infection. J. Virol. 65, 3001-3006 (1991).
38. Parren, P. W. H. I., Geisbert, T. W., Maruyama, T., Jahrling, P. B. & Burton, D. R. Pre- and postexposure prophylaxis of ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J. Virol. 76, 6408-6412 (2002).
39. Schlesinger, J. J. & Chapman, S. Neutralizing F(ab′)2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fails to protect mice against lethal YF encephalitis. J. Gen Virol. 76, 217-220 (1995).
40. Chanock, R. M., Crowe, J. E. Jr, Murphy, B. R. & Burton, D. R. Human monoclonal antibody Fab fragments cloned from combinatorial libraries: potential usefulness in prevention and/or treatment of major human viral diseases. Infect. Agents Dis. 2, 118-131 (1993).
41. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531-537 (1998).
42. Ogra, P. L., Faden, H. & Welliver, R. C. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 14, 430-445 (2001).
43. Burns, J. W., Siadat-Pajouh, M., Krishnaney, A. A. & Greenberg, H. G. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 272, 104-107 (1996).
44. + T-cell depletion in simian immunodeficiency virus-infected macaques. Exp. Med. 189, 991-998 (1999).
45. + lymphocytes. Science 283, 857-860 (1999).
46. Kaech, S. M., Wherry, E. J. & Ahmed, R. Effector and memory T-cell differentiation: implications for vaccine development. Nature Rev. Immunol. 2, 251-262 (2002).
47. McMichael, A. J. & Rowland-Jones, S. L. Cellular immune responses to HIV. Nature 410, 980-987 (2001).
48. + cytotoxic T-lymphocyte responses to lentiviruses and herpesviruses. Curr. Opin. Immunol. 13, 479-482 (2001).
49. Alexander-Miller, M. A., Leggatt, G. R. & Berzofsky, J. A. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93, 4102-4107 (1996).
50. + T cells without selection of higher affinity TCR. Nature Immunol. 2, 711-717 (2001).
51. + T-cell response to HIV-1. Curr. Opin. Immunol. 12, 381-386 (2000).
52. Kalams, S. A. & Walker, B. D. The critical need for CD4 help in maintaining effective cytotoxic T-lymphocyte responses. J. Exp. Med. 188, 2199-2204 (1998).
53. Hasenkrug, K. J. & Chesebro, B. Immunity to retroviral infection: the Friend virus model. Proc. Natl. Acad. Sci. USA 94, 7811-7816 (1997).
54. Dittmer, U., Brooks, D. M. & Hasenkrug, K. J. Requirement for multiple lymphocyte subsets in protection by a live-attenuated vaccine against retroviral infection. Nature Med. 5, 189-193 (1999).
55. Dittmer, U. & Hasenkrug, K. J. Different immunological requirements for protection against acute versus persistent friend retrovirus infections. Virology 272, 177-182 (2000).
56. Slifka, M. K. & Ahmed, R. Long-term humoral immunity against viruses: revisiting the issue of plasma-cell longevity. Trends Microbiol. 4, 394-400 (1996).
57. Slifka, M. K. & Ahmed, R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr. Opin. Immunol. 10, 252-258 (1998).
58. Ochsenbein, A. F. et al. Protective long-term antibody memory by antigen-driven and T-help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs Proc. Natl Acad. Sci. USA 97, 13263-13268 (2000).
59. Janeway, C. A. Use of concentrated human serum γ-globulin in the prevention and attenuation of measles. NY Acad. Med. 21, 202 (1945).
60. Krugman, S. The clinical use of γ-globulin. N. Engl. J. Med. 269, 195-201 (1963).
61. Copelovici, Y., Strulovici, D., Cristea, A. L., Tudor, V. & Armasu, V. Data on the efficiency of specific antimumps immunoglobulins in the prevention of mumps and of its complications. Virologie 30, 171-177 (1979).
62. Martin du Pan, R., Koechli, B. & Douath, A. Protection of nonimmune volunteers against rubella by intravenous administration of normal human γ-globulin. J. Infect. Dis. 126, 341-344 (1972).
63. Balfour, H. H. Jr et al. Prevention or modification of varicella using zoster-immune plasma. Am. J. Dis. Child. 131, 693-696 (1977).
64. Kreil, T. R., Maier, E., Fraiss, S. & Eibl, M. M. Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein. J. Virol. 72, 3076-3081 (1998).
65. Good, R. A. & Zak, S. Z. Disturbance in γ-globulin synthesis as 'experiments of nature'. Pediatrics 18, 109-149 (1956).
66. Sanna, P. P. & Burton, D. R. Role of antibodies in controlling viral disease: lessons from experiments of nature and gene knockouts. J. Virol. 74, 9813-9817 (2000).
67. Klavinskis, S., Ordstone, M. B. A. & Whitton, J. L. in Vaccines 89. Modern Approaches to New Vaccines Including Prevention of AIDS (eds Brown, F., Chanock, R., Ginsberg, H. & Lerner, R.) 485-489 (Cold Spring Harbor Laboratory Press, 1989).
68. Ulmer, J. B. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745-1749 (1993).
69. Kulkarni, A. B. et al. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. J. Virol 69, 1261-1264 (1995).
70. Hislop, A. D. et al. Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge. Nature Med. 4, 1193-1196 (1998).
71. Mateo, L., Gardner, J. & Suhrbler, A. Delayed emergence of bovine leukemia virus after vaccination with a protective cytotoxic T-cell-based vaccine. AIDS Res. Hum. Retroviruses 17, 1447-1453 (2001).
72. Shiver, J. W. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335 (2002).
73. Allen, T. M. et al. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J. Virol. 76, 4108-4112 (2002).
74. Bachmann, M. F. & Zinkernagel, R. M. The influence of virus structure on antibody responses and virus serotype formation. Immunol. Today 11, 553-558 (1996).
75. Bachmann, M. F. & Zinkernagel, R. M. Neutralizing antiviral B-cell responses. Annu. Rev. Immunol. 15, 235-270 (1997).
76. Roben, P. et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68, 4821-4828 (1994).
77. Sattentau, O. J. & Moore, J. P. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182, 185-196 (1995).
78. Sakurai, H. et al. Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines. J. Virol. 73, 2956-2962 (1999).
79. Moore, J. P. & Ho, D. D. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 9, S117-S136 (1995).
80. Parren, P. W. H. I., Sattentau, Q. J. & Burton, D. R. HIV-1 antibody - debris or virion? Nature Med. 3, 366-367 (1997).
81. Burton, D. R. & Parren, P. W. H. I. Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection? Nature Med. 6, 123-125 (2000).
82. Francis, T. Jr. Influenza: the newe acquayantance. Ann. Int. Med. 39, 203-221 (1953).
83. Davenport, F. M. & Hennessy, A. V. Predetermination by infection and by vaccination of antibody response to influenza virus vaccines. J. Exp. Med. 106, 835-850 (1957).
84. Fazekas de St. Groth, S. & Webster, R. G. Disquisitions on original antigenic sin. I. Evidence in man. J. Exp. Med. 124, 331-345 (1966).
85. East, I. J., Todd, P. E. & Leach, S. J. Original antigenic sin: experiments with a defined antigen. Mol. Immunol. 17, 1539-1544 (1980).